Listen to this page using ReadSpeaker
Archive for the Diseases Category

VISIONS 2015, Faces of VISIONS – Carol Brill

Carol Brill“If one person’s giving me a hard time, I’m not going to let him ruin my day,” says Carol Brill. “I always remember there are seven billion other people in the world who can make me happy.”
Continue Reading…

VISIONS 2015 – Dr. José Sahel Receives Foundation’s Most Prestigious Research Honor

Dr. SahelI’ve known Dr. José Sahel for more than a decade, and every time I’m with him, I’m impressed by his humility and graciousness. He’s not much for rhetoric or small talk, but is always polite and insightful. Dr. Sahel is also very soft-spoken, but I think that’s his secret weapon. He forces you to really listen to what he’s saying.
Continue Reading…

VISIONS 2015 – Dr. Shannon Boye Receives FFB Award for Excellence in Gene-Therapy Research

Shannon Boye accepting the awardWhen it comes to developing innovative gene therapies for retinal diseases, few researchers are doing more than Shannon Boye, Ph.D., and her laboratory staff of 10 at the University of Florida. In addition to advancing a gene therapy for Leber congenital amaurosis (LCA) caused by GUCY2D mutations toward a human study, Dr. Boye and her team are enhancing gene-delivery systems by making them safer to administer and able to carry larger payloads than current systems.
Continue Reading…

VISIONS 2015, Faces of VISIONS – Amy and Nathan Hayes

Amy and Nathan HayesOne of the wonderful things about the Foundation’s annual conference—taking place this year in FFB’s founding city of Baltimore—is it draws all kinds of people from around the world. And while they’ve come to gather research information and hear motivational speakers and meet others like themselves, each has his or her own story to tell.
Continue Reading…

VISIONS 2015, FFB’s National Conference — In Our Founding City!

skyline of BaltimoreIt was 44 years ago that a handful of Baltimore-area families—intent on wiping out the vision-robbing retinal diseases affecting their members—established the Foundation Fighting Blindness. They soon discovered how daunting that task would be, but also offered each other support and solace during a very dark time.
Continue Reading…

Promising Research Highlighted at Meeting of Retinal Gene Therapy Experts

genesWhen it comes to fighting blinding retinal diseases, nothing has been more exciting than the advancement of gene therapies into clinical trials. And, with human studies of gene therapies now underway for Leber congenital amaurosis (LCA, RPE65 mutations), Usher syndrome type 1B, Stargardt disease, retinoschisis, choroideremia and retinitis pigmentosa (MERTK mutations), scientists are gaining new knowledge every day about the best technologies and methodologies for gene-therapy development.
Continue Reading…

Sun and Funds: FFB’s Annual Summer Campaign

Summer Challenge web pageWe all know that Memorial Day is not, technically, the first day of summer. But seeing as we like to stretch summer out as much as possible, it only makes sense to kick it off… well… a few weeks early. The same premise is behind FFB’s Summer Challenge to End Blindness campaign, which began Memorial Day weekend and continues through the upcoming season.
Continue Reading…

ARVO 2015 Highlight: The National Eye Institute Invests $4 Million in Audacious-Goals Research

future of retinal researchThe National Eye Institute’s (NEI) establishment of its Audacious Goals in 2013 was a watershed moment in the drive to cure blinding retinal diseases. The mission of the program—to regenerate the neurons and neural connections in the eye and visual system—is synonymous with the Foundation’s mission to eradicate retinal diseases. Most important, it means that the NEI is making significant investments in research that will benefit people with retinal conditions, such as retinitis pigmentosa, Usher syndrome, Stargardt disease, and age-related macular degeneration.
Continue Reading…

ARVO 2015 Highlight: AMD Gene Therapy Performs Encouragingly in Human Study

an AMD eyeWhile treatments such as Lucentis®, Avastin®, and Eylea® have been saving and restoring vision for people with wet age-related macular degeneration (AMD) over the last several years, they have a significant drawback: The therapies require regular injections into the eye—in some cases, monthly—for the life of the patient.
Continue Reading…

ARVO 2015 Highlight: New Research Boosts Prospects for Saving Vision with RdCVF

Dr. SahelAn eye doctor could preserve meaningful vision in people with advanced retinitis pigmentosa (RP) by saving just five percent of their cones, the cells concentrated in the central retina enabling us to read, recognize colors and see in lighted conditions.
Continue Reading…